Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) dropped 26.8% on Monday . The company traded as low as $0.42 and last traded at $0.45. Approximately 86,930,683 shares were traded during trading, an increase of 196% from the average daily volume of 29,385,932 shares. The stock had previously closed at $0.61.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research note on Monday. They set a "hold" rating for the company.
View Our Latest Report on TNXP
Tonix Pharmaceuticals Price Performance
The stock has a 50 day moving average of $0.21 and a 200-day moving average of $0.41. The stock has a market capitalization of $75.34 million, a P/E ratio of -0.01 and a beta of 2.23. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $1.80. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, equities research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.
About Tonix Pharmaceuticals
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Stories
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.